FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2323679294> ?p ?o ?g. }

• W2323679294 endingPage "377" @default.
• W2323679294 startingPage "377.2" @default.
• W2323679294 abstract "<h3>Background</h3> A reduction in peripheral blood neutrophils count is usually observed with the anti-interleukin (IL) 6 receptor antibody tocilizumab. This often appears few days after first administration, but mechanisms are not completely established. <h3>Objectives</h3> To evaluate the evolution of neutrophils count under tocilizumab (anti IL-6R) treatment for rheumatoid arthritis affected patients and to correlate this evolution with clinical response. <h3>Methods</h3> We performed a multicentric retrospective study including patients with RA treated by tocilizumab +/– DMARDs in 4 University French Centers (Bordeaux, Clermont-Ferrand, Limoges and Montpellier). Neutrophils, inflammatory parameters and DAS28 (ESR) were recorded at baseline, and after one and three months of treatment. The comparisons were performed using Student’s t-test or Mann-Whitney test when appropriate. A statistical significant p-value of 0,05 was selected. <h3>Results</h3> 122 patients were included with mean age of 59,9±12,6 years-old and a mean disease duration of 13,2±9,5 years. The mean DAS28 (ESR) at inclusion was about 5,25±1,22, and decreased significantly after one month of treatment to 3,71±1,35 (p<10^-4), and to 3,14±1,32 (p<10^-4) after three months of treatment. According to the EULAR response criteria, 2 patients were classified as good responders (1,6%), 95 as moderate responders (77,9%) and 25 as non-responders (20,5%). The neutrophils count shows a significant decrease between the introduction of tocilizumab therapy and after one month of treatment (5815±2514/mm³ vs. 4085±2433/mm³, p<10^-4), whereas it stays at the same level between the first and the third month of treatment (4014±2428/mm³ vs. 4225±2342/mm³, p=0,27). The frequency of neutropenia (neutrophils≤1500/mm³) was about 0,8% (1/122) at inclusion, 4,9% (6/122) after one month and 3,3% (4/122) after three months of treatment. The neutrophils count decreases significantly between the inclusion and first month of treatment in the subgroup of Month 3 responders (6111±2850/mm³ vs. 3987±2407, p<10^-4 with Mann-Whitney test), whereas this decrease is not significant in the subgroup of month 3 non-responders (5510±2360/mm³ vs. 4320±2458/mm³, p=0,12 with Mann-Whitney test). The DAS (ESR) difference between Month 0 and Month 3 was positively correlated with the difference of the neutrophils count between Month 0 and Month 1 (p=0,04; r=0,19). <h3>Conclusions</h3> This study reveals correlation between neutrophils decrease and clinical response during tocilizumab therapy. Accordingly with our previous report showing decrease of myeloid dendritic cells and monocytes during tocilizumab therapy, these new data suggest a specific effect of tocilizumab on cells from myeloid lineage. <h3>Disclosure of Interest</h3> None Declared" @default.
• W2323679294 created "2016-06-24" @default.
• W2323679294 creator A5013402679 @default.
• W2323679294 creator A5017802262 @default.
• W2323679294 creator A5026359062 @default.
• W2323679294 creator A5031868807 @default.
• W2323679294 creator A5044373758 @default.
• W2323679294 creator A5061482669 @default.
• W2323679294 creator A5071044231 @default.
• W2323679294 creator A5074863723 @default.
• W2323679294 date "2013-06-01" @default.
• W2323679294 modified "2023-09-27" @default.
• W2323679294 title "FRI0192 Is early neutropenia associated with clinical response in patients receiving tocilizumab in rheumatoid arthritis?" @default.
• W2323679294 doi "https://doi.org/10.1136/annrheumdis-2012-eular.2649" @default.
• W2323679294 hasPublicationYear "2013" @default.
• W2323679294 type Work @default.
• W2323679294 sameAs 2323679294 @default.
• W2323679294 citedByCount "0" @default.
• W2323679294 crossrefType "journal-article" @default.
• W2323679294 hasAuthorship W2323679294A5013402679 @default.
• W2323679294 hasAuthorship W2323679294A5017802262 @default.
• W2323679294 hasAuthorship W2323679294A5026359062 @default.
• W2323679294 hasAuthorship W2323679294A5031868807 @default.
• W2323679294 hasAuthorship W2323679294A5044373758 @default.
• W2323679294 hasAuthorship W2323679294A5061482669 @default.
• W2323679294 hasAuthorship W2323679294A5071044231 @default.
• W2323679294 hasAuthorship W2323679294A5074863723 @default.
• W2323679294 hasConcept C126322002 @default.
• W2323679294 hasConcept C12868164 @default.
• W2323679294 hasConcept C141071460 @default.
• W2323679294 hasConcept C198451711 @default.
• W2323679294 hasConcept C2776694085 @default.
• W2323679294 hasConcept C2777063308 @default.
• W2323679294 hasConcept C2777077863 @default.
• W2323679294 hasConcept C2777178219 @default.
• W2323679294 hasConcept C2777575956 @default.
• W2323679294 hasConcept C2781059491 @default.
• W2323679294 hasConcept C71924100 @default.
• W2323679294 hasConcept C74133956 @default.
• W2323679294 hasConcept C90924648 @default.
• W2323679294 hasConceptScore W2323679294C126322002 @default.
• W2323679294 hasConceptScore W2323679294C12868164 @default.
• W2323679294 hasConceptScore W2323679294C141071460 @default.
• W2323679294 hasConceptScore W2323679294C198451711 @default.
• W2323679294 hasConceptScore W2323679294C2776694085 @default.
• W2323679294 hasConceptScore W2323679294C2777063308 @default.
• W2323679294 hasConceptScore W2323679294C2777077863 @default.
• W2323679294 hasConceptScore W2323679294C2777178219 @default.
• W2323679294 hasConceptScore W2323679294C2777575956 @default.
• W2323679294 hasConceptScore W2323679294C2781059491 @default.
• W2323679294 hasConceptScore W2323679294C71924100 @default.
• W2323679294 hasConceptScore W2323679294C74133956 @default.
• W2323679294 hasConceptScore W2323679294C90924648 @default.
• W2323679294 hasIssue "Suppl 3" @default.
• W2323679294 hasLocation W23236792941 @default.
• W2323679294 hasOpenAccess W2323679294 @default.
• W2323679294 hasPrimaryLocation W23236792941 @default.
• W2323679294 hasRelatedWork W189077404 @default.
• W2323679294 hasRelatedWork W1987294331 @default.
• W2323679294 hasRelatedWork W2110315816 @default.
• W2323679294 hasRelatedWork W2323679294 @default.
• W2323679294 hasRelatedWork W2591383409 @default.
• W2323679294 hasRelatedWork W2736593664 @default.
• W2323679294 hasRelatedWork W2766107824 @default.
• W2323679294 hasRelatedWork W2920685979 @default.
• W2323679294 hasRelatedWork W2970100988 @default.
• W2323679294 hasRelatedWork W2996380604 @default.
• W2323679294 hasVolume "71" @default.
• W2323679294 isParatext "false" @default.
• W2323679294 isRetracted "false" @default.
• W2323679294 magId "2323679294" @default.
• W2323679294 workType "article" @default.